ArticlePatient preference and adherence2020

Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.

Martine C Maculaitis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.